ResMed Inc. 10-Q Summary: Period Ended December 31, 2002
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep disordered breathing (primarily obstructive sleep apnea). The reporting period covers the three and six months ended December 31, 2002. Manufacturing operations are located in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2002 | Six Months Ended Dec 31, 2002 |
|---|---|---|
| Net Revenue | $65.3 million | $123.9 million |
| Gross Profit | $41.8 million | $79.5 million |
| Gross Margin | 64% | 64% |
| Operating Income | $16.1 million | $31.6 million |
| Net Income | $10.4 million | $20.0 million |
| Diluted EPS | $0.30 | $0.58 |
| Cash from Operations (6mo) | $20.2 million | |
| Cash & Equivalents (Dec 31, 2002) | $82.5 million | |
| Convertible Notes Outstanding | $113.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 33% ($16.4 million) for the quarter and 30% ($28.8 million) for the six months compared to the prior year periods. Growth was driven by increased sales of flow generators, masks, and accessories, as well as the inclusion of Servo Magnetics Inc. (acquired May 2002) and favorable foreign currency translation.
- Margin Compression: Gross margin decreased slightly to 64% from 65% (quarter) and 66% (six months) in the prior year. This was attributed to higher manufacturing costs due to a stronger Australian dollar and the inclusion of lower-margin motor sales from Servo Magnetics.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 41% for the quarter, driven by increased personnel, litigation costs ($0.7 million), and currency effects. R&D expenses increased 33% due to higher personnel costs and clinical trial fees.
- Debt Reduction: The company repurchased $10.0 million face value of convertible subordinated notes during the six-month period, recognizing a gain of $0.3 million.
Outlook, Risks, and Unusual Items
- Capital Expenditures: Significant spending ($10.6 million for six months) is directed toward a new manufacturing facility in Sydney, Australia, with an estimated total future cost of $30.0 million for the first building.
- Acquisitions: Acquired John Stark and Associates for $300,000 in July 2002. The Servo Magnetics acquisition (May 2002) contributed $1.7 million in sales for the quarter.
- Legal Proceedings: Active patent litigation against Respironics (ongoing since 1995 and new 2002 filing) and Fisher & Paykel Healthcare (filed August 2002). Management believes outcomes will not have a material adverse effect, but no assurance is given.
- Foreign Exchange Risk: The company faces significant exposure to the Australian dollar and Euro. A stronger Australian dollar negatively impacted gross margins. The company utilizes foreign currency options to hedge these risks.
- Stock Repurchases: Repurchased 125,318 shares of common stock for $3.5 million during the six-month period under a board authorization.
Investor Verification Checklist
- Foreign Currency Impact: Verify the sensitivity of future margins to fluctuations in the Australian dollar, given that a majority of manufacturing costs are incurred in Australia.
- Patent Litigation Status: Monitor the progress of the 1995 and 2002 lawsuits against Respironics and the 2002 suit against Fisher & Paykel, as adverse rulings could impact market share or require licensing fees.
- Capital Project Execution: Track the completion timeline and cost overruns for the new Sydney manufacturing facility, which represents a significant future cash outflow.
- Acquisition Integration: Assess the integration performance of Servo Magnetics Inc. and the realization of projected synergies.
- Debt Conversion Risk: Review the terms of the $113.3 million convertible notes (due 2006) and the potential for future dilution if stock prices exceed conversion thresholds.